[Clinical and pharmacological studies of the second generation antipsychotics].
Kuroki
T
T
Tashiro
N
N
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines; D003024:Clozapine; D003072:Cognition Disorders / Q000188:drug therapy; D003598:Cytoskeletal Proteins / Q000378:metabolism; D003987:Dibenzothiazepines; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D006801:Humans; D009419:Nerve Tissue Proteins / Q000378:metabolism; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D000069348:Quetiapine Fumarate; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy; D012702:Serotonin Antagonists
D014150:Antipsychotic Agents; D003598:Cytoskeletal Proteins; D003987:Dibenzothiazepines; D018492:Dopamine Antagonists; D009419:Nerve Tissue Proteins; D016760:Proto-Oncogene Proteins c-fos; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C092069:activity regulated cytoskeletal-associated protein; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine; D004298:Dopamine